140,147,153,155,159 However, statins are known to exhibit high interindividual variability in terms of pharmacokinetics, and GLP-1 RA administration did not affect the lipid-lowering effect of statins in clinical studies, indicating minimal clinical significance
Researchers designed it specifically to optimize certain properties, enhanced stability, targeted follicle activity, and reduced interference with other biological processes
Silva-Adaya D, PrezDe La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villeda-Hernndez J, Binienda Z, et al
[63] Survodutide, Mazdutide, Pemvidutide, MariTide, Ecnoglutide, and Bimagrumab Other emerging therapies include dual GLP-1/glucagon receptor agonists such as survodutide, mazdutide, and pemvidutide, long-acting antibody-based or peptide-conjugate approaches such as maridebart cafraglutide (MariTide), biased GLP-1 receptor agonists such as ecnoglutide, and body-composition-targeted therapies such as bimagrumab, which targets activin type II receptors to reduce fat mass while preserving or increasing lean mass